Identifying gut microbiota with high specificity for ischemic stroke with large vessel occlusion

Ping He,Chen Jiang,Jianqiang Ni,Xiaoxuan Zhang,Zhifeng Wu,Gengjing Chen,Jin Huang,Zheng Dai,Wei Ji,Lei Li,Kefei Chen,Yachen Shi
DOI: https://doi.org/10.1038/s41598-024-64819-6
IF: 4.6
2024-06-20
Scientific Reports
Abstract:Gut microbiota can regulate the metabolic and immunological aspects of ischemic stroke and modulate the treatment effects. The present study aimed to identify specific changes in gut microbiota in patients with large vessel occlusion (LVO) ischemic stroke and assess the potential association between gut microbiota and clinical features of ischemic stroke. A total of 63 CSVD patients, 64 cerebral small vessel disease (CSVD) patients, and 36 matching normal controls (NCs) were included in this study. The fecal samples were collected for all participants and analyzed for gut microbiota using 16S rRNA gene sequencing technology. The abundances of five gut microbiota, including genera Bifidobacterium, Butyricimonas, Blautia, and Dorea and species Bifidobacterium_longum, showed significant changes with high specificity in the LVO patients as compared to the NCs and CSVD patients. In LVO patients, the genera Bifidobacterium and Blautia and species Bifidobacterium_longum were significantly correlated with the National Institutes of Health Stroke Scale (NIHSS) scores at the admission and discharge of the patients. Serum triglyceride levels could significantly affect the association of the abundance of genus Bifidobacterium and species Bifidobacterium_longum with the NIHSS scores at admission and modified Rankin Scale (mRS) at discharge in LVO patients. The identification of five gut microbiota with high specificity were identified in the early stage of LVO stroke, which contributed to performed an effective clinical management for LVO ischemic stroke.
multidisciplinary sciences
What problem does this paper attempt to address?
The paper aims to address the specific changes in the gut microbiota of patients with large vessel occlusion (LVO) ischemic stroke and to evaluate the potential associations between these microbiota and stroke clinical characteristics. Specifically, the study found the following points: 1. **Changes in Gut Microbiota Diversity**: There are significant differences in the diversity of gut microbiota among LVO stroke patients, cerebral small vessel disease (CSVD) patients, and normal control groups, indicating that the microbiota richness is higher in the LVO group. 2. **Changes in Specific Microbiota**: In LVO stroke patients, the genera Bifidobacterium, Butyricimonas, Blautia, and Dorea, as well as the species Bifidobacterium longum, showed significant specific changes, with their relative abundances differing markedly compared to the normal control group and CSVD patients. 3. **Relationship with Stroke Severity and Metabolism**: In LVO stroke patients, the genera Bifidobacterium, Blautia, and the species Bifidobacterium longum are significantly associated with stroke severity and lipid and glucose metabolism. 4. **Mediating Role of Triglyceride Levels**: Triglyceride (TG) levels act as an important mediator, influencing the relationship between the relative abundance of the genera Bifidobacterium and the species Bifidobacterium longum and stroke severity at admission (measured by NIHSS score). 5. **Association with Functional Outcomes**: The relative abundances of the genera Bifidobacterium, Blautia, and the species Bifidobacterium longum are associated with the functional outcomes at discharge in LVO stroke patients. Therefore, the study identified five gut microbiota that are highly specific in the early stages of LVO stroke, which helps in the effective clinical management of LVO ischemic stroke.